Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Empresa holandesa ofrece cooperación y tecnologías para mejorar la producción de proteínas biofarmacéuticas y desarrollar líneas celulares

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TONL20181212001
Publicado:
26/03/2019
Caducidad:
26/03/2020
Resumen:
Una empresa holandesa ofrece una tecnología de aplicación general para generar líneas celulares superiores destinada a la producción de proteínas biofarmacéuticas. La aplicación de la tecnología permite que las células cultivadas de mamífero produzcan más proteínas recombinantes por célula. La empresa ha descubierto e implementado elementos genéticos y ha desarrollado plataformas de producción muy rentables para producir proteínas recombinantes. Actualmente se centra en dos tipos de productos: biosimilares (productos biofarmacéuticos genéricos) y proteínas difíciles de expresar (proteínas de fusión fc, proteínas biespecíficas, proteínas de membrana y proteínas de subunidad múltiple). La empresa busca compañías biotecnológicas, farmacéuticas y de diagnóstico para participar en proyectos sobre desarrollo de productos y tecnologías de producción y establecer acuerdos de comercialización, investigación y cooperación técnica.

Details

Tittle:
Dutch SME offers cooperation and technology for production improvement of biopharmaceutical proteins and cell line development
Summary:
A Dutch company offers a generally applicable technology to generate superior cell lines for biopharmaceutical protein production. Application of the technology allows cultured mammalian cells to produce more recombinant protein per cell. The company is looking for cooperation projects involving product and production technology development and for commercial agreement with biotech, pharma and diagnostic companies. A research cooperation agreement or a technical cooperation agreement is foreseen
Description:
Biopharmaceuticals are typically produced in cultured mammalian cells. The complex development and manufacturing method of these medicinal products results in their high pricing.

A Dutch biotech company has discovered and implemented genetic elements and developed highly cost-effective, production platforms for recombinant pharmaceutical proteins. Application of the technology increases production levels 2 to 3-fold compared to other systems commonly in use in the industry, resulting into improved efficiencies and lower production costs. Proof of value was demonstrated in different Chinese hamster ovary (CHO) cell types (e.g. adherent and suspension CHO-K1, CHO-DG44, CHO-GS) with different selection markers (e.g. blasticidin, puromycin, zeocin) for various proteins (e.g. monoclonal antibodies, biosimilars, difficult to express proteins).

Currently the Dutch SME focuses on two product classes: i. Biosimilars (generic biopharmaceuticals) and ii. difficult-to-express proteins (e.g. Fc-fusion proteins, bispecific proteins, membrane proteins, large multiple subunit proteins). For the latter, production inefficiencies currently prevent commercially viable levels and therefore inhibit their development. The technology is licensed to pharma companies.

The technology is patented, generally applicable (cell types, selection markers, expressed proteins), awarded and commercialized by licensing to pharmaceutical companies.

The SME is seeking collaboration with partners from companies and academia related to its expertise on producing proteins.

A research cooperation agreement is foreseen or a technical cooperation agreement, but also other types of collaboration can be discussed.
The cooperation types represents a broad range of R-Y-D topics, such as the devolpment of mammalian cell-produced products and studying biopharmaceutical protein variants.
Advantages and Innovations:
The SME´s technology has the advantage that it allows more efficient production of biopharmaceutical proteins. For biosimilar this relates to facilitating protein production with high yield and at low costs.

For difficult to express proteins two important issues related to their production and limited availability can be solved: the inability to produce these proteins at commercially viable levels and the inability to easily prepare sufficient material to develop these kind of drug towards clinical studies.

Besides increasing its toolbox of genetic elements the Dutch SME also innovates by facilitating implementation of the technology and develop the technology towards a plug and play system.
Stage of Development:
Already on the market
IPs:
Secret Know-how,Patent(s) applied for but not yet granted,Patents granted
CommeR Statunts Regarding IPR Status:
The technology is patented and generally applicable (e.g. cell types, selection markers, expressed proteins).
Patents have been applied and granted in the relevant regions: Europe, US, Australia, Canada and China.

Partner sought

Type and Role of Partner Sought:
The company is seeking collaboration with other companies (SME´s) and academia related to its expertise on producing proteins for development and research.

This represents a broad range of R-Y-D topics. Partners from different application fields are invited, including partners developing mammalian cell-produced products, partners aiming to improve production by process engineering, partners interested in developing and studying biopharmaceutical protein variants, partners carrying out studies relating to protein production yield or its related metabolic processes, etc.

The Dutch SME is seeking both technical as well as research cooperation´s. It is interested in different programs, like Eurostars and FTI, as well as participation in consortia created to address topic-specific Horizon2020 and Horizon Europe calls.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Dutch
English
German
Spanish

Keywords

Technology Keywords:
06002009 Diseño molecular
006002003 Enzymology/Protein Engineering/Fermentation
06003002 Expresión genética, investigación proteómica
06001009 Terapia genética - ADN